Fig. 1 · Structure

Documents & Downloads

BC2059

Cat. No. A14381 CAS 1227637-23-1

beta-catenin inhibitor

BC2059 is an orally bioavailable and potent beta-catenin inhibitor.

In Stock

Publications for BC2059

1 publication citing this product

  1. Ji-Hye Jung, .et al. , Stem Cells Dev, 2016, Jul 1; 25(13): 1006-1019 PMID: 27188501

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In AML cells, BC2059 reduced the TBL1–β-catenin association. Carfilzomib restored β-catenin protein depleted by BC2059, supporting proteasome involvement. These cellular experiments do not establish a direct binding affinity. [1]

Mechanistic responses vary by model. In DLBCL cells, tegavivint disrupted TBL1–β-catenin association, but MYC transcript was unchanged or increased and β-catenin knockdown had little effect on viability. A separate HEK 293 study found no consistent suppression of Wnt-stimulated reporter output by tegavivint despite cell death in a separate exposure experiment. Wnt inhibition should therefore not be assumed to explain every cytotoxic response. [2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 0.05169 μM Growth inhibition of human A549 cells after 72 hrs by APH assay [PMID: 26182238]
Cancer cell lines IC50 0.02001 μM Cytotoxicity against human breast cancer cell aggregates grown on matrigel incubated for 72 hrs by MTS assay [PMID: 26182238]
Cancer cell lines IC50 0.02075 μM Cytotoxicity against human prostate cancer cells after 72 hrs by MTS assay [PMID: 26182238]
Cancer cell lines IC50 0.02992 μM Cytotoxicity against human colon cancer cell aggregates grown on matrigel incubated for 72 hrs by MTS assay [PMID: 26182238]
Cancer cell lines IC50 0.5305 μM Cytotoxicity against human ovarian cancer cell aggregates grown on matrigel incubated for 72 hrs by MTS assay [PMID: 26182238]
HCT-116 IC50 0.02019 μM Growth inhibition of human HCT116 cells after 72 hrs by APH assay [PMID: 26182238]
HCT-15 IC50 0.03057 μM Growth inhibition of human HCT15 cells after 72 hrs by APH assay [PMID: 26182238]
HCT-15 IC50 0.03806 μM Cytotoxicity against human HCT15 cell aggregates grown on matrigel incubated for 72 hrs by MTS assay [PMID: 26182238]
HT-29 GI50 0.09 μM Growth inhibition of human HT-29 cells after 72 hrs by APH assay [PMID: 26182238]
HT-29 IC50 0.63 μM Inhibition of Wnt/beta-catenin transcriptional activity in human HT-29 cells assessed as depletion of beta-catenin level by TCF luciferase promoter reporter assay [PMID: 26182238]
MCF7 IC50 0.08078 μM Growth inhibition of human MCF7 cells after 72 hrs by APH assay [PMID: 26182238]
SW480 IC50 0.02329 μM Growth inhibition of human SW480 cells after 72 hrs by APH assay [PMID: 26182238]

12 records · Scroll to view more

BC2059 Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of BC2059 from 4 published references. In vitro models include HEK 293 TCF/LEF luciferase reporter cells.

BC2059 In Vitro Studies

In H1 and iPSC-2 human pluripotent stem cells, 100 nM BC2059 for 24 hours decreased OCT4, NANOG, REX1 and hTERT transcripts relative to DMSO. The authors used Adooq BC2059 (A14381); the study does not validate a current product lot. [4]

AML TBL1–β-catenin complex disruption and proteasome control

Cell-based study · HL-60 and OCI-AML3 cells; primary FLT3-ITD and FLT3 wild-type AML cells [1]

BC2059 reduced co-immunoprecipitated TBL1–β-catenin in cultured and primary AML cells. In cultured cells, carfilzomib restored β-catenin protein, supporting proteasome involvement; this is cellular complex evidence, not a purified-protein binding affinity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TBL1-associated β-catenin, with reciprocal IP in cultured cellsqualitative response Reduced after BC2059 versus 0 nM; input and IgG controls displayed[1]
β-catenin protein with carfilzomib controlqualitative response Carfilzomib restored β-catenin depleted by BC2059; c-RAF was not depleted by BC2059[1]

Literature-Reported Treatment Conditions

Treatment concentration
Cultured cells: 100 nM BC2059; primary FLT3-ITD: 100 nM; primary FLT3-WT: 50, 100, 200 nM (Figure 2A,B). Proteasome control: 100 nM BC2059 ± 10 nM carfilzomib (Figure 2D).
Exposure duration
8 h
Method
Co-immunoprecipitation/immunoblot; whole-cell immunoblot with β-actin loading control
Vehicle
Untreated (0 nM) comparator; vehicle identity not specified for these panels
Co-treatment
Carfilzomib only for the proteasome-control experiment; single-agent BC2059 complex-disruption panels kept distinct
Reported limits
Exact n for the Figure 2 blots is not stated in the caption. No quantitative dissociation constant is established by this design.
Methods and source locations

Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: BC2059

Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.

Figure 2A,B,D and caption; Results: Treatment with BC2059 disrupts the binding of β-catenin and TBL1; Reagents and antibodies; Immunoprecipitation

TBL1-associated β-catenin, with reciprocal IP in cultured cells: Co-IP and immunoblot — Figure 2A,B; caption

β-catenin protein with carfilzomib control: Immunoblot; carfilzomib-alone and combination controls; β-actin loading control — Figure 2D; corresponding Results

Stemness and hTERT marker response in human pluripotent stem cells

Cell-based study · H1 human embryonic stem cells and iPSC-2 for qPCR; hPSCs for the representative immunoblot [4]

BC2059 decreased OCT4, NANOG, REX1 and hTERT transcripts in the displayed H1 and iPSC-2 comparisons. The representative immunoblot showed decreased β-catenin and phosphorylated mTOR/p70S6K.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
OCT4, NANOG, REX1 and hTERT mRNA relative to DMSOqualitative response Decreased in both displayed cell lines; no exact fold changes extracted[4]
β-catenin, phospho-mTOR and phospho-p70S6K proteinqualitative response Decreased in the representative BC2059 lane compared with DMSO[4]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
24 h
Method
qPCR and western blotting
Vehicle
DMSO comparator shown in Figure 5E–G
Reported limits
The caption does not identify the hPSC line in panel G. Do not assign the PNU-74654 proliferation experiments in Figure 5A–D to BC2059.
Methods and source locations

Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: BC2059

Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.

Figure 5E–G and caption; Results: β-catenin influence on hPSC fate with the correlation of mTOR; Antibodies and reagents; Cell culture; Western blotting

OCT4, NANOG, REX1 and hTERT mRNA relative to DMSO: qPCR; Figure 5 caption reports means ± SD after GAPDH normalization — Figure 5E,F; caption; associated Results

β-catenin, phospho-mTOR and phospho-p70S6K protein: Western blot; total mTOR, total p70S6K and β-actin displayed — Figure 5G; corresponding Results

DLBCL protein-complex response and β-catenin dependence controls

Cell-based study · Riva, OCI-Ly3, Pfeiffer and WSU-NHL DLBCL cells; Riva and Pfeiffer for co-IP/ChIP [2]

Tegavivint disrupted the TBL1/β-catenin association and reduced β-catenin promoter recruitment, yet MYC transcript did not fall. β-catenin knockdown had minimal effects on cell viability or MYC/SURVIVIN protein, limiting a purely β-catenin-dependent explanation in these models.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TBL1–β-catenin association and MYC/BIRC5 promoter occupancyqualitative response Association and β-catenin recruitment decreased; TBL1 recruitment unaffected[2]
MYC protein and MYC mRNAqualitative response MYC protein decreased at 24 h; MYC transcript increased in Riva and Pfeiffer and did not change in OCI-Ly3 or WSU-NHL at 12 h[2]
MYC/SURVIVIN protein and cell viability after β-catenin knockdownqualitative response No significant viability effect (P>0.05); MYC and SURVIVIN not significantly affected as reported in Results[2]

Literature-Reported Treatment Conditions

Treatment concentration
Riva and Pfeiffer: 70 nM; OCI-Ly3: 50 nM; WSU-NHL: 15 nM (Figure 4 caption, all drug experiments)
Exposure duration
12 h for co-IP/PLA, ChIP and qRT-PCR; 24 h for drug-treatment immunoblots. Genetic-control viability: 72 h post-transduction.
Method
Co-IP/PLA, ChIP, immunoblot and qRT-PCR; β-catenin knockdown as mechanistic control
Vehicle
DMSO (NT) drug control; genetic control for knockdown
Reported limits
These cellular experiments do not measure direct binding affinity. No drug dose is assigned to the genetic-only controls.
Methods and source locations

Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: tegavivint

Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.

Figure 4A–F and caption; Results: TBL1 modulates Wnt targets in a novel, post-transcriptional, β-CATENIN independent manner; shared Methods; Supplementary Appendix pp1,4–5

TBL1–β-catenin association and MYC/BIRC5 promoter occupancy: Co-IP includes IgG; ChIP includes preimmune control; n=3, means ± SEM for ChIP — Figure 4A,B; caption

MYC protein and MYC mRNA: Immunoblot with GAPDH loading control; qRT-PCR, n=3, means ± SEM — Figure 4C,E; caption; associated Results

MYC/SURVIVIN protein and cell viability after β-catenin knockdown: Two β-catenin-targeting shRNAs; control comparator; trypan-blue viability, n=3, means ± SEM — Figure 4F and caption

Wnt reporter and cell-death comparison in engineered HEK 293 cells

Cell-based study · HEK 293 TCF/LEF luciferase reporter cells (BPS Bioscience 60501) [3]

Tegavivint did not consistently suppress Wnt-stimulated reporter output under the tested conditions, whereas IWR-1-endo did. Tegavivint caused cell death in a separate 24-hour comparison, unlike IWR-1-endo.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Wnt3a-stimulated TCF/LEF reporter luminescencequalitative response Tegavivint versus DMSO: ns; IWR-1-endo significantly reduced signal[3]
SYTOX Green-positive dead-cell objectsqualitative response Tegavivint induced cell death at 24 h; IWR-1-endo was not lethal[3]

Literature-Reported Treatment Conditions

Treatment concentration
Reporter panel: tegavivint 1 μM; IWR-1-endo 1 μM. Death panel: tegavivint 1.25 μM; IWR-1-endo 1 μM.
Exposure duration
4 h compound exposure for reporter panel (figure label); 24 h for separate cell-death panel
Method
Luminescence normalized to DMSO/Wnt3a; cell death measured by SYTOX Green-positive object counts
Vehicle
DMSO; reporter background from DMSO without Wnt3a
Co-treatment
Wnt3a stimulation in the reporter assay; IWR-1-endo and CIL56 are separate comparator arms, not combination drugs
Reported limits
Methods also describe sublethal 100 nM tegavivint experiments; those are not assigned to the displayed 1 μM panel. These results do not prove the absence of TBL1 binding.
Methods and source locations

Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: tegavivint

Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.

Figure 5f,g and caption; Results: Tegavivint does not inhibit the Wnt/β-catenin pathway; Methods: Chemicals, Cell lines and culture conditions, β-catenin reporter assays

Wnt3a-stimulated TCF/LEF reporter luminescence: One-way ANOVA with Tukey posthoc tests; individual datapoints from three or more independent experiments; no precise effect magnitude inferred — Figure 5f and caption; β-catenin reporter assay methods

SYTOX Green-positive dead-cell objects: Dead-cell imaging; individual datapoints from three or more independent experiments — Figure 5g and caption

BC2059 In Vivo Studies

In a disseminated Riva lymphoma model, tegavivint at 25 mg/kg intravenously every 3 days from day 7 prolonged median survival to 33 days versus 27 days with vehicle (n=5/group; P=0.0031). Four of five treated mice died with CNS involvement despite minimal systemic disease, limiting the response. [2]

Riva lymphoma xenograft survival with CNS progression limitation

Animal study · NSG mice bearing disseminated Riva ABC-DLBCL; randomized, n=5/group [2]

Tegavivint prolonged median survival relative to vehicle, with residual CNS disease limiting the response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival from engraftment to clinical removal endpointmedian survival 33 days (tegavivint) versus 27 days (vehicle); P=0.0031; n=5/group[2]
CNS disease in treated animalsreported count 4 of 5 treated mice died with CNS involvement despite minimal systemic disease[2]

Conditions shared by the study groups

Route
Intravenous, tail vein
Frequency
Every 3 days
Treatment course
Starting day 7 after engraftment; no fixed total course stated in text
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tegavivint versus vehicle
25 mg/kg
Vehicle-treated mice; n=5 per groupMedian survival 33 versus 27 days; P=0.0031 (log-rank). Four of five treated mice had CNS involvement at death despite minimal systemic disease.[2]
Tegavivint versus vehicle
Model: Seven-week-old NSG mice bearing disseminated Riva ABC-DLBCL
Reported limits: Vehicle composition and mouse sex not reported in the selected main text or relevant supplement methods.
Methods and source locations

Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: tegavivint

Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.

Figure 3C and caption; Results: TBL1 is critical for diffuse large B-cell lymphoma cell survival (Riva drug experiment); Supplementary Appendix Animal studies p8; Reagents p1

Survival from engraftment to clinical removal endpoint: Kaplan–Meier, log-rank test; endpoint defined in Supplementary Appendix p8 — Figure 3C caption and Results

CNS disease in treated animals: Reported terminal disease findings; representative brain histology shown — Figure 3C and associated Results

Tegavivint versus vehicle · Figure 3C and caption; Results: TBL1 is critical for diffuse large B-cell lymphoma cell survival (Riva drug experiment); Supplementary Appendix Animal studies p8; Reagents p1

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1227637-23-1
Applications beta-catenin inhibitor
Formula C28H36N4O6S2
Molecular Weight 588.74
SMILES
O=S(C1=CC2=C(C=C1)/C(C3=CC=C(S(=O)(N4C[C@H](C)C[C@H](C)C4)=O)C=C3/C2=N\O)=N\O)(N5C[C@H](C)C[C@H](C)C5)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL
Water 88 mg/mL
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

BC2059 Research References

  1. [1] Fiskus W, Sharma S, Saha S, et al. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia (2015). PMID: 25482131 DOI: 10.1038/leu.2014.340 Source material
  2. [2] Youssef Y, Karkhanis V, Chan WK, et al. Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma. Haematologica (2021). PMID: 33054136 DOI: 10.3324/haematol.2020.268235 Source material
  3. [3] Leak L, Wang Z, Joseph AJ, et al. Tegavivint triggers TECR-dependent nonapoptotic cancer cell death. Nature chemical biology (2025). PMID: 40419770 DOI: 10.1038/s41589-025-01913-4 Source material
  4. [4] Jung JH, Kang KW, Kim J, et al. CXCR2 Inhibition in Human Pluripotent Stem Cells Induces Predominant Differentiation to Mesoderm and Endoderm Through Repression of mTOR, β-Catenin, and hTERT Activities. Stem cells and development (2016). PMID: 27188501 DOI: 10.1089/scd.2015.0395 Source material

Publications

1 publication citing this product

  1. Ji-Hye Jung, .et al. , Stem Cells Dev, 2016, Jul 1; 25(13): 1006-1019 PMID: 27188501

Added to your cart

View Cart Checkout
Loading...